Molenaar Nienke, Bijkerk Ronald M, Beishuizen Albertus, Hempen Christel M, de Jong Margriet F C, Vermes Istvan, van der Sluijs Veer Gertjan, Girbes Armand R J, Groeneveld A B Johan
Crit Care. 2012 Jul 10;16(4):R121. doi: 10.1186/cc11415.
This study was aimed at characterizing basal and adrenocorticotropic hormone (ACTH)-induced steroidogenesis in sepsis and nonsepsis patients with a suspicion of critical illness-related corticosteroid insufficiency (CIRCI), taking the use of etomidate-inhibiting 11β-hydroxylase into account.
This was a prospective study in a mixed surgical/medical intensive care unit (ICU) of a university hospital. The patients were 62 critically ill patients with a clinical suspicion of CIRCI. The patients underwent a 250-μg ACTH test (n = 67). ACTH, adrenal steroids, substrates, and precursors (modified tandem mass spectrometry) also were measured. Clinical characteristics including use of etomidate to facilitate intubation (n = 14 within 72 hours of ACTH testing) were recorded.
At the time of ACTH testing, patients had septic (n = 43) or nonseptic critical illness (n = 24). Baseline cortisol directly related to sepsis and endogenous ACTH, independent of etomidate use. Etomidate was associated with a lower baseline cortisol and cortisol/11β-deoxycortisol ratio as well as higher 11β-deoxycortisol, reflecting greater 11β-hydroxylase inhibition in nonsepsis than in sepsis. Cortisol increases < 250 mM in exogenous ACTH were associated with relatively low baseline (HDL-) cholesterol, and high endogenous ACTH with low cortisol/ACTH ratio, independent of etomidate. Although cortisol increases with exogenous ACTH, levels were lower in sepsis than in nonsepsis patients, and etomidate was associated with diminished increases in cortisol with exogenous ACTH, so that its use increased, albeit nonsignificantly, low cortisol increases to exogenous ACTH from 38% to 57%, in both conditions.
A single dose of etomidate may attenuate stimulated more than basal cortisol synthesis. However, it may only partly contribute, particularly in the stressed sepsis patient, to the adrenal dysfunction of CIRCI, in addition to substrate deficiency.
本研究旨在描述脓毒症和疑似患有危重病相关皮质类固醇功能不全(CIRCI)的非脓毒症患者的基础及促肾上腺皮质激素(ACTH)诱导的类固醇生成情况,同时考虑依托咪酯对11β-羟化酶的抑制作用。
这是一项在大学医院外科/内科混合重症监护病房(ICU)进行的前瞻性研究。研究对象为62例临床疑似患有CIRCI的危重病患者。这些患者接受了250μg促肾上腺皮质激素试验(n = 67)。同时还测量了促肾上腺皮质激素、肾上腺类固醇、底物和前体(改良串联质谱法)。记录了包括使用依托咪酯辅助插管(促肾上腺皮质激素检测72小时内n = 14)在内的临床特征。
在促肾上腺皮质激素检测时,患者患有脓毒症(n = 43)或非脓毒症危重病(n = 24)。基线皮质醇与脓毒症和内源性促肾上腺皮质激素直接相关,与依托咪酯的使用无关。依托咪酯与较低的基线皮质醇和皮质醇/11β-脱氧皮质醇比值以及较高的11β-脱氧皮质醇相关,这反映出非脓毒症患者中11β-羟化酶的抑制作用比脓毒症患者更强。外源性促肾上腺皮质激素刺激后皮质醇升高<250 mM与相对较低的基线(高密度脂蛋白)胆固醇相关,而内源性促肾上腺皮质激素水平高与皮质醇/促肾上腺皮质激素比值低相关,与依托咪酯无关。尽管外源性促肾上腺皮质激素刺激后皮质醇升高,但脓毒症患者的皮质醇水平低于非脓毒症患者,并且依托咪酯与外源性促肾上腺皮质激素刺激后皮质醇升高幅度减小有关,因此在两种情况下,其使用均使外源性促肾上腺皮质激素刺激后皮质醇低升高比例虽无显著增加,但从38%增至57%。
单剂量依托咪酯可能对刺激后的皮质醇合成抑制作用大于基础皮质醇合成。然而,除底物缺乏外,它可能仅在一定程度上导致,尤其是在应激的脓毒症患者中,CIRCI的肾上腺功能障碍。